A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)
Publication date: September 2026 Source: International Journal of Lung Cancer, Volume 1, Issue 3 Author(s): Kota Kawabata, Keita Miura, Yasushi Goto, Yoshimasa Shiraishi, Shogo Nomura, Noriko Mitome, Haruhiko Fukuda, Isamu Okamoto, Hirotsugu Kenmotsu, the Lung Cancer Study Group of the Japan Clinical Oncology Group
A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA). // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000513?dgcid=rss_sd_all
A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA). JAAD International. https://www.sciencedirect.com/science/article/pii/S3117504X26000513?dgcid=rss_sd_all
“A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA).” JAAD International.
@article{article5815,
title = {A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000513?dgcid=rss_sd_all}
}